Abbott Laboratories

New York Stock Exchange
Back to all articles
Neutral +10

Abbott Laboratories $ABT Position Reduced by Bank of Nova Scotia

AI-generated analysis

📉 Bank of Nova Scotia trimmed its Abbott Laboratories position by 16.8% in Q1, selling 52,490 shares while retaining a stake worth $26.67 million.

📈 Freemont Management S.A. significantly increased its holding by 197.2% in Q4 to own 10,700 shares valued at $1.34 million.

💰 PFA Pension Forsikringsaktieselskab established a new stake in Abbott Laboratories worth approximately $116.58 million during the fourth quarter.

📊 JPMorgan Chase raised its price target for ABT from $110 to $120 and reaffirmed an overweight rating on July 17th.

📉 Mizuho decreased its price target from $125 to $115 and set a neutral rating in a report dated April 17th.

💵 Abbott Laboratories declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 15th.

👔 Director Daniel J. Starks purchased 10,000 shares at an average cost of $92.65 in April, increasing his total ownership to over 6.75 million shares.

📈 The company currently trades with a market cap of $179.63 billion and a P/E ratio of 33.38.

🏥 Abbott operates globally through diagnostics, medical devices, nutritionals, and established pharmaceuticals segments.

Bullish Signals
  • Multiple institutional investors increased their stakes in the fourth quarter, including Freemont Management S.A., PFA Pension Forsikringsaktieselskab, Thrivent Financial, and Mn Services Vermogensbeheer B.V.
  • Director Daniel J. Starks acquired an additional 10,000 shares of common stock, signaling continued insider confidence in the company's long-term prospects.
  • JPMorgan Chase increased its price target to $120 and Piper Sandler raised its objective to $118, indicating bullish sentiment from major financial institutions.
  • The company maintains a strong balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
Risk Factors
  • Mizuho lowered its price target to $115 and assigned a neutral rating, suggesting potential concerns about near-term performance or valuation.
  • Argus reduced its price target from $140 to $125, indicating a bearish shift in expectations for the stock's upside potential.
  • The dividend payout ratio is high at 81.55%, which may limit flexibility for future capital expenditures or share buybacks if earnings growth slows.
Full Analysis
Bank of Nova Scotia reduced its position in Abbott Laboratories (NYSE:ABT) by 16.8% in the first quarter, selling 52,490 shares to hold a remaining stake valued at $26.67 million. Conversely, several other institutional investors increased their holdings during the fourth quarter, including Freemont Management S.A., which grew its stake by 197.2%, and PFA Pension Forsikringsaktieselskab, which purchased a new position worth approximately $116.58 million. Analyst sentiment regarding Abbott Laboratories remains mixed with varying price targets. Mizuho and Argus lowered their price targets to $115 and $125 respectively, while JPMorgan Chase raised its target to $120 with an overweight rating. Piper Sandler also increased its objective to $118. The consensus average target price stands at $118.61, supported by a majority of analysts maintaining Buy or Overweight ratings. Abbott Laboratories reported a quarterly dividend of $0.63 per share payable on August 17th for shareholders of record on July 15th, yielding 2.4%. The company maintains a market capitalization of $179.63 billion and a P/E ratio of 33.38. Director Daniel J. Starks also acquired 10,000 shares in April, increasing his total ownership to over 6.75 million shares valued at roughly $625 million.